Edesa Biotech Posts Narrower Loss in Q3

Edesa Biotech (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory and immune-related diseases, released its fiscal third quarter results on August 8, 2025, covering the period ended June 30, 2025. The company reported a GAAP EPS loss of $(0.25), outperforming the $(0.26) consensus estimate by $0.01, or 3.8% (GAAP). Revenue (GAAP) remained at $0, matching expectations and consistent with its pre-commercial status. Operating expenses (GAAP) held steady year over year, and Net loss (GAAP) was nearly unchanged. At June 30, 2025, Edesa had cash and cash equivalents of $12.4 million. Overall, the period was marked by stable financials, careful spending, and focused progress on its lead clinical assets. Source: Analyst estimates for the quarter provided by FactSet. Edesa Biotech is a biopharmaceutical firm dedicated to developing new therapies for conditions with significant unmet medical needs. Its core strategy centers on immune and inflammatory diseases, targeting indications where existing treatments fall short. These include dermatological and respiratory diseases.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool